New drug interaction study aims to make camizestrant safer

NCT ID NCT06547164

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed phase 1 study looked at how the experimental cancer drug camizestrant affects the breakdown of midazolam (a sedative) and how carbamazepine (a seizure drug) affects camizestrant levels. Forty healthy postmenopausal women took part. The goal was to gather safety and dosing information, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Camizestrant (AZD9833), midazolam, carbamazepine
What this could lead to: If successful, this study will help doctors understand how camizestrant interacts with other drugs, leading to safer dosing recommendations for future patients.
What could go wrong: This is an early-phase, small study in healthy volunteers, not patients. Results may not predict effects in people with cancer or those taking other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Show contact details

Locations

Research Site

Harrow, HA1 3UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.